Medical Gas Regulation; Public Workshops; Request for Comments, 54353-54355 [2017-24918]

Download as PDF Federal Register / Vol. 82, No. 221 / Friday, November 17, 2017 / Notices 54353 TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1—Continued Number of responses per respondent Number of respondents Type of interview Total annual responses Average burden per response Total hours Usability Testing Screener ................................. 2,028 1 2,028 0.083 (5 minutes) ........ 168 Total ............................................................ .......................... .......................... ........................ ..................................... 10,622 1 There are no capital costs or operating and maintenance costs associated with this collection of information. The number of respondents to be included in each new pretest may vary, depending on the nature of the material or message being tested and the target audience. Table 1 provides examples of the types of studies that may be administered and estimated burden levels during the 3-year period. Time to read, view, or listen to the message being tested is built into the ‘‘Hours per Response’’ figures. The burden for this collection has decreased by 18,437 hours from 29,059 to 10,622. FDA attributes this decrease to assessing the planned studies for the next 3 years. Dated: November 9, 2017. Anna K. Abram, Deputy Commissioner for Policy, Planning, Legislation, and Analysis. [FR Doc. 2017–24924 Filed 11–16–17; 8:45 am] BILLING CODE 4164–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA–2017–N–0001] Medical Gas Regulation; Public Workshops; Request for Comments AGENCY: Food and Drug Administration, HHS. Notice of public workshops; request for comments. ACTION: The Food and Drug Administration (FDA, the Agency, or we) is announcing two public workshops entitled ‘‘Medical Gas Regulation: Workshop I’’ and ‘‘Medical Gas Regulation: Workshop II.’’ The topic to be discussed is potential areas of Federal drug regulation that should be revised with respect to medical gases. DATES: The first public workshop will be held on December 15, 2017, from 9 a.m. to 5 p.m. The second public workshop will be held on February 9, 2018, from 9 a.m. to 5 p.m. However, depending on the level of public participation, the workshops may end early. FDA may announce additional public workshop dates in the future, if needed. sradovich on DSK3GMQ082PROD with NOTICES SUMMARY: VerDate Sep<11>2014 18:32 Nov 16, 2017 Jkt 244001 Submit either electronic or written comments on these public workshops by March 15, 2018, for Workshop I, and by May 10, 2018, for Workshop II. See the SUPPLEMENTARY INFORMATION section for registration dates and information. ADDRESSES: The public workshops will be held at FDA’s White Oak Campus, 10903 New Hampshire Ave., Bldg. 31 Conference Center, Rm. 1503 B–C (sections B and C of the ‘‘Great Room’’), Silver Spring, MD 20993–0002. Entrance for public workshop participants (non-FDA employees) is through Building 1 where routine security-check procedures will be performed. For parking and security information, please refer to https:// www.fda.gov/AboutFDA/ WorkingatFDA/BuildingsandFacilities/ WhiteOakCampusInformation/ ucm241740.htm. You may submit comments as follows. Please note that late, untimely filed comments may not be considered. For timely consideration, we request that electronic comments on workshop topics be submitted before or within 90 days after each workshop (i.e., comments should be submitted by or before March 15, 2018, for Workshop I, and May 10, 2018, for Workshop II). FDA will have one shared docket for all workshops. The https:// www.regulations.gov electronic filing system will accept comments until midnight Eastern Time at the end of May 10, 2018. Comments received by mail/hand delivery/courier (for written/ paper submissions) will be considered timely if they are postmarked or the delivery service acceptance receipt is on or before the relevant date. Electronic Submissions Submit electronic comments in the following way: • Federal eRulemaking Portal: https://www.regulations.gov. Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to https:// www.regulations.gov will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any PO 00000 Frm 00038 Fmt 4703 Sfmt 4703 confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else’s Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on https://www.regulations.gov. • If you want to submit a comment with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission and in the manner detailed (see ‘‘Written/Paper Submissions’’ and ‘‘Instructions’’). Written/Paper Submissions Submit written/paper submissions as follows: • Mail/Hand delivery/Courier (for written/paper submissions): Dockets Management Staff (HFA–305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. • For written/paper comments submitted to the Dockets Management Staff, FDA will post your comment, as well as any attachments, except for information submitted, marked and identified, as confidential, if submitted as detailed in ‘‘Instructions.’’ Instructions: All submissions received must include the Docket No. FDA– 2017–N–0001 for ‘‘Medical Gas Regulation.’’ Received comments, those filed in a timely manner (see ADDRESSES), will be placed in the docket and, except for those submitted as ‘‘Confidential Submissions,’’ publicly viewable at https://www.regulations.gov or at the Dockets Management Staff between 9 a.m. and 4 p.m., Monday through Friday. • Confidential Submissions—To submit a comment with confidential information that you do not wish to be made publicly available, submit your comments only as a written/paper submission. You should submit two copies total. One copy will include the information you claim to be confidential with a heading or cover note that states ‘‘THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.’’ The Agency will review this copy, including E:\FR\FM\17NON1.SGM 17NON1 54354 Federal Register / Vol. 82, No. 221 / Friday, November 17, 2017 / Notices the claimed confidential information, in its consideration of comments. The second copy, which will have the claimed confidential information redacted/blacked out, will be available for public viewing and posted on https://www.regulations.gov. Submit both copies to the Dockets Management Staff. If you do not wish your name and contact information to be made publicly available, you can provide this information on the cover sheet and not in the body of your comments and you must identify this information as ‘‘confidential.’’ Any information marked as ‘‘confidential’’ will not be disclosed except in accordance with 21 CFR 10.20 and other applicable disclosure law. For more information about FDA’s posting of comments to public dockets, see 80 FR 56469, September 18, 2015, or access the information at: https://www.gpo.gov/ fdsys/pkg/FR-2015-09-18/pdf/201523389.pdf. Docket: For access to the docket to read background documents or the electronic and written/paper comments received, go to https:// www.regulations.gov and insert the docket number, found in brackets in the heading of this document, into the ‘‘Search’’ box and follow the prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. FOR FURTHER INFORMATION CONTACT: Christine Kirk, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Silver Spring, MD 20993–0002, 301–796–2465, Fax: 301– 847–8440, email: MedgasPublicWorkshops@fda.hhs.gov. SUPPLEMENTARY INFORMATION: sradovich on DSK3GMQ082PROD with NOTICES I. Background On May 5, 2017, President Trump signed the Consolidated Appropriations Act, 2017 (Pub. L. 115–31). Section 756 of the Consolidated Appropriations Act, 2017 requires FDA to issue final regulations revising Federal drug regulations with respect to medical gases. These public workshops are being held as part of FDA’s implementation of the requirements of section 756. Since the 2012 enactment of the Food and Drug Administration Safety and Innovation Act (FDASIA) (Pub. L. 112– 144), FDA has engaged in multiple activities related to medical gases, including rulemaking. For example, in 2016, FDA issued the final rule ‘‘Medical Gas Containers and Closures: Current Good Manufacturing Practice Requirements’’ (81 FR 81685, November 18, 2016). Other activities include FDA’s June 2017 revised draft guidance VerDate Sep<11>2014 18:32 Nov 16, 2017 Jkt 244001 for industry on current good manufacturing practice for medical gases,1 updated guidance for FDA inspectors regarding medical gases (March 2015),2 an extensive review of Federal drug regulations related to medical gases from 2012 to 2014 (a report on the review was submitted to Congress in 2015),3 and implementation of FDASIA’s requirements regarding certification of medical gases (to date, over 70 certifications have been granted). FDA intends to engage in additional rulemaking in this area in accordance with section 756 of the Consolidated Appropriations Act, 2017. To conduct rulemaking as efficiently as possible, FDA intends to build on the information and stakeholder input received since FDASIA’s enactment. As noted in more detail below, FDA invites comments from stakeholders on specific medical gas issues that could or should be addressed in regulation. II. Topics for Discussion at the Public Workshops We are holding these workshops to provide an opportunity for medical gas manufacturers and any other interested members of the public to provide input on potential areas of Federal drug regulation that should be revised with respect to medical gases. We are asking stakeholders to comment on existing medical gas issues which, in their view, should be addressed by regulation change (rather than through other means, such as revisions to guidance or inspection practices). Commenters should include concrete and specific reasons that rulemaking is preferable to other options. Commenters’ views regarding the prioritization of particular rulemaking proposals would also be helpful. If a stakeholder would like a comment to be discussed at a particular public workshop, it should be submitted with a discussion request by no later than 1 week before the date of the workshop. If a stakeholder would like a comment to be included in FDA’s consideration of public comments presented and received for a particular workshop, it should be submitted no later than 90 days after the date of the workshop. As noted above, the https:// 1 Available at: https://www.fda.gov/ucm/groups/ fdagov-public/@fdagov-drugs-gen/documents/ document/ucm070270.pdf. 2 Available at: https://www.fda.gov/downloads/ ICECI/ComplianceManuals/ ComplianceProgramManual/UCM125417.pdf. 3 Available at: https://www.fda.gov/downloads/ regulatoryinformation/lawsenforcedbyfda/ significantamendmentstothefdcact/fdasia/ ucm453727.pdf. PO 00000 Frm 00039 Fmt 4703 Sfmt 4703 www.regulations.gov electronic filing system will accept comments until midnight Eastern Time at the end of May 10, 2018. Late comments will not be considered. During Workshop I (December 2017), FDA intends to discuss the anticipated scope of the medical gas rulemaking, as well as three regulations to which stakeholders have previously requested changes: 21 CFR part 201 (labeling generally and labeling for medical air specifically), 21 CFR part 207 (registration and listing), and 21 CFR parts 210 and 211 (current good manufacturing practice). Depending on the number of speakers and time available, we may also consider comments on additional regulations. During Workshop II (February 2018), FDA intends to discuss 21 CFR part 314 (adverse event reporting) and the intersection of regulations for medical gases and regulations for medical devices and animal drugs. Depending on the number of speakers and time available, we may also consider comments on additional regulations and medical gas issues not currently addressed in regulation. FDA is considering whether to schedule one or more additional public workshops in 2018 to hear from stakeholders regarding any remaining topics. III. Participating in the Public Workshops Registration: The workshops are free and seating will be on a first-come, firstserved basis. Attendees who do not wish to make an oral presentation do not need to register. If you need special accommodations because of a disability, please contact MedgGasPublicWorkshops@fda.hhs.gov (or see FOR FURTHER INFORMATION CONTACT) at least 7 days in advance of each workshop. Requests for Oral Presentations: If you wish to a make an oral presentation, you must register by submitting your name, title, firm name, address, telephone, email address, and Fax number to MedgasPublicWorkshops@fda.hhs.gov (see FOR FURTHER INFORMATION CONTACT) by December 8, 2017, for Workshop I, or February 2, 2018, for Workshop II. Please also indicate the type of organization you represent (e.g., industry, consumer organization) and a brief summary of your remarks (including the discussion topic(s) that you would like to address). FDA will try to accommodate all persons who wish to make a presentation; however, the duration of each speaker’s presentation may be limited by time constraints. FDA will notify registered presenters of their E:\FR\FM\17NON1.SGM 17NON1 Federal Register / Vol. 82, No. 221 / Friday, November 17, 2017 / Notices scheduled presentation times. Persons registered to speak should check in before the workshops and are encouraged to arrive early to ensure their designated order of presentation. Participants who are not present when called may not be permitted to speak at a later time. An agenda will be made available at least 3 days before each workshop at https://www.fda.gov/ Drugs/NewsEvents/ucm582091.htm. FDA may also post specific questions for consideration at the meeting Web page; these will be made available at least 3 days before each workshop at https://www.fda.gov/Drugs/NewsEvents/ ucm582091.htm. Streaming Webcast and Video of the Public Workshops: These public workshops will be webcast; the URL will be posted at https://www.fda.gov/ Drugs/NewsEvents/ucm582091.htm at least 1 day before each workshop. A video record of the public workshops will be available at the same Web site address for 1 year. Dated: November 13, 2017. Leslie Kux, Associate Commissioner for Policy. [FR Doc. 2017–24918 Filed 11–16–17; 8:45 am] BILLING CODE 4164–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA–2013–N–0878] Agency Information Collection Activities; Proposed Collection; Comment Request; Premarket Notification for a New Dietary Ingredient AGENCY: Food and Drug Administration, HHS. ACTION: Notice. The Food and Drug Administration (FDA or Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on the procedure by which a manufacturer or distributor of a new dietary ingredient or of a dietary supplement containing a new dietary ingredient is to submit to FDA sradovich on DSK3GMQ082PROD with NOTICES SUMMARY: VerDate Sep<11>2014 18:32 Nov 16, 2017 Jkt 244001 information upon which it has based its conclusion that a dietary supplement containing the new dietary ingredient will reasonably be expected to be safe. DATES: Submit either electronic or written comments on the collection of information by January 16, 2018. ADDRESSES: You may submit comments as follows. Please note that late, untimely filed comments will not be considered. Electronic comments must be submitted on or before January 16, 2018. The https://www.regulations.gov electronic filing system will accept comments until midnight Eastern Time at the end of January 16, 2018. Comments received by mail/hand delivery/courier (for written/paper submissions) will be considered timely if they are postmarked or the delivery service acceptance receipt is on or before that date. Electronic Submissions Submit electronic comments in the following way: • Federal eRulemaking Portal: https://www.regulations.gov. Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to https:// www.regulations.gov will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else’s Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on https://www.regulations.gov. • If you want to submit a comment with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission and in the manner detailed (see ‘‘Written/Paper Submissions’’ and ‘‘Instructions’’). Written/Paper Submissions Submit written/paper submissions as follows: • Mail/Hand delivery/Courier (for written/paper submissions): Dockets Management Staff (HFA–305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. • For written/paper comments submitted to the Dockets Management Staff, FDA will post your comment, as well as any attachments, except for information submitted, marked and PO 00000 Frm 00040 Fmt 4703 Sfmt 4703 54355 identified, as confidential, if submitted as detailed in ‘‘Instructions.’’ Instructions: All submissions received must include the Docket No. FDA– 2013–N–0878 for ‘‘Premarket Notification for a New Dietary Ingredient.’’ Received comments, those filed in a timely manner (see ADDRESSES), will be placed in the docket and, except for those submitted as ‘‘Confidential Submissions,’’ publicly viewable at https://www.regulations.gov or at the Dockets Management Staff between 9 a.m. and 4 p.m., Monday through Friday. • Confidential Submissions—To submit a comment with confidential information that you do not wish to be made publicly available, submit your comments only as a written/paper submission. You should submit two copies total. One copy will include the information you claim to be confidential with a heading or cover note that states ‘‘THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.’’ The Agency will review this copy, including the claimed confidential information, in its consideration of comments. The second copy, which will have the claimed confidential information redacted/blacked out, will be available for public viewing and posted on https://www.regulations.gov. Submit both copies to the Dockets Management Staff. If you do not wish your name and contact information to be made publicly available, you can provide this information on the cover sheet and not in the body of your comments and you must identify this information as ‘‘confidential.’’ Any information marked as ‘‘confidential’’ will not be disclosed except in accordance with 21 CFR 10.20 and other applicable disclosure law. For more information about FDA’s posting of comments to public dockets, see 80 FR 56469, September 18, 2015, or access the information at: https://www.gpo.gov/ fdsys/pkg/FR-2015-09-18/pdf/201523389.pdf. Docket: For access to the docket to read background documents or the electronic and written/paper comments received, go to https:// www.regulations.gov and insert the docket number, found in brackets in the heading of this document, into the ‘‘Search’’ box and follow the prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. Ila Mizrachi, Office of Operations, Food and Drug Administration, Three White Flint North, 10A–12M, 11601 Landsdown St., North Bethesda, MD FOR FURTHER INFORMATION CONTACT: E:\FR\FM\17NON1.SGM 17NON1

Agencies

[Federal Register Volume 82, Number 221 (Friday, November 17, 2017)]
[Notices]
[Pages 54353-54355]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-24918]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2017-N-0001]


Medical Gas Regulation; Public Workshops; Request for Comments

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of public workshops; request for comments.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA, the Agency, or we) is 
announcing two public workshops entitled ``Medical Gas Regulation: 
Workshop I'' and ``Medical Gas Regulation: Workshop II.'' The topic to 
be discussed is potential areas of Federal drug regulation that should 
be revised with respect to medical gases.

DATES: The first public workshop will be held on December 15, 2017, 
from 9 a.m. to 5 p.m. The second public workshop will be held on 
February 9, 2018, from 9 a.m. to 5 p.m. However, depending on the level 
of public participation, the workshops may end early. FDA may announce 
additional public workshop dates in the future, if needed.
    Submit either electronic or written comments on these public 
workshops by March 15, 2018, for Workshop I, and by May 10, 2018, for 
Workshop II. See the SUPPLEMENTARY INFORMATION section for registration 
dates and information.

ADDRESSES: The public workshops will be held at FDA's White Oak Campus, 
10903 New Hampshire Ave., Bldg. 31 Conference Center, Rm. 1503 B-C 
(sections B and C of the ``Great Room''), Silver Spring, MD 20993-0002. 
Entrance for public workshop participants (non-FDA employees) is 
through Building 1 where routine security-check procedures will be 
performed. For parking and security information, please refer to 
https://www.fda.gov/AboutFDA/WorkingatFDA/BuildingsandFacilities/WhiteOakCampusInformation/ucm241740.htm.
    You may submit comments as follows. Please note that late, untimely 
filed comments may not be considered. For timely consideration, we 
request that electronic comments on workshop topics be submitted before 
or within 90 days after each workshop (i.e., comments should be 
submitted by or before March 15, 2018, for Workshop I, and May 10, 
2018, for Workshop II). FDA will have one shared docket for all 
workshops. The https://www.regulations.gov electronic filing system 
will accept comments until midnight Eastern Time at the end of May 10, 
2018. Comments received by mail/hand delivery/courier (for written/
paper submissions) will be considered timely if they are postmarked or 
the delivery service acceptance receipt is on or before the relevant 
date.

Electronic Submissions

    Submit electronic comments in the following way:
     Federal eRulemaking Portal: https://www.regulations.gov. 
Follow the instructions for submitting comments. Comments submitted 
electronically, including attachments, to https://www.regulations.gov 
will be posted to the docket unchanged. Because your comment will be 
made public, you are solely responsible for ensuring that your comment 
does not include any confidential information that you or a third party 
may not wish to be posted, such as medical information, your or anyone 
else's Social Security number, or confidential business information, 
such as a manufacturing process. Please note that if you include your 
name, contact information, or other information that identifies you in 
the body of your comments, that information will be posted on https://www.regulations.gov.
     If you want to submit a comment with confidential 
information that you do not wish to be made available to the public, 
submit the comment as a written/paper submission and in the manner 
detailed (see ``Written/Paper Submissions'' and ``Instructions'').

Written/Paper Submissions

    Submit written/paper submissions as follows:
     Mail/Hand delivery/Courier (for written/paper 
submissions): Dockets Management Staff (HFA-305), Food and Drug 
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
     For written/paper comments submitted to the Dockets 
Management Staff, FDA will post your comment, as well as any 
attachments, except for information submitted, marked and identified, 
as confidential, if submitted as detailed in ``Instructions.''
    Instructions: All submissions received must include the Docket No. 
FDA-2017-N-0001 for ``Medical Gas Regulation.'' Received comments, 
those filed in a timely manner (see ADDRESSES), will be placed in the 
docket and, except for those submitted as ``Confidential Submissions,'' 
publicly viewable at https://www.regulations.gov or at the Dockets 
Management Staff between 9 a.m. and 4 p.m., Monday through Friday.
     Confidential Submissions--To submit a comment with 
confidential information that you do not wish to be made publicly 
available, submit your comments only as a written/paper submission. You 
should submit two copies total. One copy will include the information 
you claim to be confidential with a heading or cover note that states 
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will 
review this copy, including

[[Page 54354]]

the claimed confidential information, in its consideration of comments. 
The second copy, which will have the claimed confidential information 
redacted/blacked out, will be available for public viewing and posted 
on https://www.regulations.gov. Submit both copies to the Dockets 
Management Staff. If you do not wish your name and contact information 
to be made publicly available, you can provide this information on the 
cover sheet and not in the body of your comments and you must identify 
this information as ``confidential.'' Any information marked as 
``confidential'' will not be disclosed except in accordance with 21 CFR 
10.20 and other applicable disclosure law. For more information about 
FDA's posting of comments to public dockets, see 80 FR 56469, September 
18, 2015, or access the information at: https://www.gpo.gov/fdsys/pkg/FR-2015-09-18/pdf/2015-23389.pdf.
    Docket: For access to the docket to read background documents or 
the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in 
the heading of this document, into the ``Search'' box and follow the 
prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane, 
Rm. 1061, Rockville, MD 20852.

FOR FURTHER INFORMATION CONTACT: Christine Kirk, Center for Drug 
Evaluation and Research, Food and Drug Administration, 10903 New 
Hampshire Ave., Silver Spring, MD 20993-0002, 301-796-2465, Fax: 301-
847-8440, email: MedgasPublicWorkshops@fda.hhs.gov.

SUPPLEMENTARY INFORMATION:

I. Background

    On May 5, 2017, President Trump signed the Consolidated 
Appropriations Act, 2017 (Pub. L. 115-31). Section 756 of the 
Consolidated Appropriations Act, 2017 requires FDA to issue final 
regulations revising Federal drug regulations with respect to medical 
gases. These public workshops are being held as part of FDA's 
implementation of the requirements of section 756.
    Since the 2012 enactment of the Food and Drug Administration Safety 
and Innovation Act (FDASIA) (Pub. L. 112-144), FDA has engaged in 
multiple activities related to medical gases, including rulemaking. For 
example, in 2016, FDA issued the final rule ``Medical Gas Containers 
and Closures: Current Good Manufacturing Practice Requirements'' (81 FR 
81685, November 18, 2016). Other activities include FDA's June 2017 
revised draft guidance for industry on current good manufacturing 
practice for medical gases,\1\ updated guidance for FDA inspectors 
regarding medical gases (March 2015),\2\ an extensive review of Federal 
drug regulations related to medical gases from 2012 to 2014 (a report 
on the review was submitted to Congress in 2015),\3\ and implementation 
of FDASIA's requirements regarding certification of medical gases (to 
date, over 70 certifications have been granted).
---------------------------------------------------------------------------

    \1\ Available at: https://www.fda.gov/ucm/groups/fdagov-public/@fdagov-drugs-gen/documents/document/ucm070270.pdf.
    \2\ Available at: https://www.fda.gov/downloads/ICECI/ComplianceManuals/ComplianceProgramManual/UCM125417.pdf.
    \3\ Available at: https://www.fda.gov/downloads/regulatoryinformation/lawsenforcedbyfda/significantamendmentstothefdcact/fdasia/ucm453727.pdf.
---------------------------------------------------------------------------

    FDA intends to engage in additional rulemaking in this area in 
accordance with section 756 of the Consolidated Appropriations Act, 
2017. To conduct rulemaking as efficiently as possible, FDA intends to 
build on the information and stakeholder input received since FDASIA's 
enactment. As noted in more detail below, FDA invites comments from 
stakeholders on specific medical gas issues that could or should be 
addressed in regulation.

II. Topics for Discussion at the Public Workshops

    We are holding these workshops to provide an opportunity for 
medical gas manufacturers and any other interested members of the 
public to provide input on potential areas of Federal drug regulation 
that should be revised with respect to medical gases.
    We are asking stakeholders to comment on existing medical gas 
issues which, in their view, should be addressed by regulation change 
(rather than through other means, such as revisions to guidance or 
inspection practices). Commenters should include concrete and specific 
reasons that rulemaking is preferable to other options. Commenters' 
views regarding the prioritization of particular rulemaking proposals 
would also be helpful. If a stakeholder would like a comment to be 
discussed at a particular public workshop, it should be submitted with 
a discussion request by no later than 1 week before the date of the 
workshop. If a stakeholder would like a comment to be included in FDA's 
consideration of public comments presented and received for a 
particular workshop, it should be submitted no later than 90 days after 
the date of the workshop. As noted above, the https://www.regulations.gov electronic filing system will accept comments until 
midnight Eastern Time at the end of May 10, 2018. Late comments will 
not be considered.
    During Workshop I (December 2017), FDA intends to discuss the 
anticipated scope of the medical gas rulemaking, as well as three 
regulations to which stakeholders have previously requested changes: 21 
CFR part 201 (labeling generally and labeling for medical air 
specifically), 21 CFR part 207 (registration and listing), and 21 CFR 
parts 210 and 211 (current good manufacturing practice). Depending on 
the number of speakers and time available, we may also consider 
comments on additional regulations.
    During Workshop II (February 2018), FDA intends to discuss 21 CFR 
part 314 (adverse event reporting) and the intersection of regulations 
for medical gases and regulations for medical devices and animal drugs. 
Depending on the number of speakers and time available, we may also 
consider comments on additional regulations and medical gas issues not 
currently addressed in regulation. FDA is considering whether to 
schedule one or more additional public workshops in 2018 to hear from 
stakeholders regarding any remaining topics.

III. Participating in the Public Workshops

    Registration: The workshops are free and seating will be on a 
first-come, first-served basis. Attendees who do not wish to make an 
oral presentation do not need to register.
    If you need special accommodations because of a disability, please 
contact MedgGasPublicWorkshops@fda.hhs.gov (or see FOR FURTHER 
INFORMATION CONTACT) at least 7 days in advance of each workshop.
    Requests for Oral Presentations: If you wish to a make an oral 
presentation, you must register by submitting your name, title, firm 
name, address, telephone, email address, and Fax number to 
MedgasPublicWorkshops@fda.hhs.gov (see FOR FURTHER INFORMATION CONTACT) 
by December 8, 2017, for Workshop I, or February 2, 2018, for Workshop 
II. Please also indicate the type of organization you represent (e.g., 
industry, consumer organization) and a brief summary of your remarks 
(including the discussion topic(s) that you would like to address).
    FDA will try to accommodate all persons who wish to make a 
presentation; however, the duration of each speaker's presentation may 
be limited by time constraints. FDA will notify registered presenters 
of their

[[Page 54355]]

scheduled presentation times. Persons registered to speak should check 
in before the workshops and are encouraged to arrive early to ensure 
their designated order of presentation. Participants who are not 
present when called may not be permitted to speak at a later time. An 
agenda will be made available at least 3 days before each workshop at 
https://www.fda.gov/Drugs/NewsEvents/ucm582091.htm. FDA may also post 
specific questions for consideration at the meeting Web page; these 
will be made available at least 3 days before each workshop at https://www.fda.gov/Drugs/NewsEvents/ucm582091.htm.
    Streaming Webcast and Video of the Public Workshops: These public 
workshops will be webcast; the URL will be posted at https://www.fda.gov/Drugs/NewsEvents/ucm582091.htm at least 1 day before each 
workshop. A video record of the public workshops will be available at 
the same Web site address for 1 year.

    Dated: November 13, 2017.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2017-24918 Filed 11-16-17; 8:45 am]
 BILLING CODE 4164-01-P